# A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

> **NCT05431777** · — · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 79 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT05431777
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-19
- **Primary completion:** 2023-01-16
- **Final completion:** 2023-01-16
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431777, "A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05431777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*